# Core 2: Glioblastoma Biorepository Core

> **NIH NIH P01** · BRIGHAM AND WOMEN'S HOSPITAL · 2024 · $126,370

## Abstract

PROJECT SUMMARY – CORE 2
The goals of the Glioblastoma Biorepository Core (Core 2) are to provide all P01 members with centralized
access to professional banking of samples, patient derived models (PDX/cell lines), neuropathology services
and expertise. This includes access to human tumors derived from rQNestin clinical trial patients as well as
newly created human and mouse cell lines and xenografts critical to all experimental Project aims. The presence
of the Core ensures that all resources are clinically and molecularly annotated with respect to relevant
parameters with the goal to aid study and development of oncolytic virus and study of immunotherapy
approaches. These resources will specifically aid the projects in their studies of oncolytic virus biology,
immunology, and therapeutics in a manner not possible though individual project (e.g. R01) funding mechanisms
or through existing cores at each of the P01 institutions. Moreover, by interacting with multiple projects and
investigators, the Core will continue to act as a resource that drives collaboration and sharing of the pathological
results and findings across the P01. Core 2 has 3 Specific Aims to accomplish its goals. Aim 1: To generate
and maintain a repository of consented glioblastoma samples and data. (all Projects) which includes critical
samples and pre- post-rQNestin trial patient samples and models for study. Aim 2: To create and distribute
glioblastoma patient derived cell lines (PDCL) and xenografts (PDX) (all Projects) which will be used to study
patterns of infection and effects of novel oHSV derivatives. Aim 3: To provide expert neuropathology,
immunopathology, and molecular analysis of glioblastoma tissues and models (all Projects) including novel
digital pathology deep-learning algorithms and multiplex immunofluorescence. In summary, the Core services
will be essential to all Projects and will promote and prioritize collaboration to develop more effective oncolytic
viral therapies for GBM and other cancers.

## Key facts

- **NIH application ID:** 10931407
- **Project number:** 5P01CA163205-12
- **Recipient organization:** BRIGHAM AND WOMEN'S HOSPITAL
- **Principal Investigator:** KEITH LLOYD LIGON
- **Activity code:** P01 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2024
- **Award amount:** $126,370
- **Award type:** 5
- **Project period:** 2013-02-07 → 2028-08-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10931407

## Citation

> US National Institutes of Health, RePORTER application 10931407, Core 2: Glioblastoma Biorepository Core (5P01CA163205-12). Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/grant/nih/10931407. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*